Close Menu

NEW YORK (GenomeWeb) – EntroGen said today that it has received CE-IVD marking for its BRCA Complete kit for exome sequencing of the BRCA1 and BRCA2 genes.

The test is a targeted next-generation sequencing assay for use on Illumina's MiniSeq, MiSeq, and NextSeq platforms. It can detect somatic mutations in BRCA1 and BRCA2 with limit of detection of roughly 2 percent and uniformity and average sequencing coverage of 95 percent and 0.2X, respectively, the company said.

The kit also comes with data interpretation software for reporting clinically relevant mutations.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
22
Sponsored by
Qiagen

Please join GenomeWeb and Qiagen for an online roundtable discussion where a panel of experts will review challenges and opportunities around genomic variant interpretation workflows in the field of oncology.

Feb
23
Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Feb
24
Sponsored by
SCHOTT MINIFAB

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints.